Biomea Fusion Stock Surges on Phase II Diabetes Trial Enrollment Completion
Shares of Biomea Fusion are trading sharply higher on Monday following an operational milestone for its lead metabolic drug program.
Biomea Fusion finished signing up all the patients it needed for an important test of a new diabetes medicine. This is a good checkpoint, but it just means they can move forward—the real test is whether the medicine actually works.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.